Skip Ribbon Commands
Skip to main content

Holmium-166 SIRT Scout dose QuiremScout® awarded top 3 most innovative medical device in the 2019 Belgian Galenus prize

12/9/2020 - LEUVEN, BELGIUM

Terumo Europe N.V. is awarded top 3 innovative medical device in the 2019 Belgian Galenus prize with the innovative Holmium-166 SIRT diagnostic scout dose product QuiremScout®.

The Galenus prize recognizes and rewards outstanding achievements that improve the global human condition through the development of innovative therapies1. It was created in France in 1970 by a pharmacist named Roland Mehl with the aim to advance pharmaceutical research. Recently, the Prix Galien award is also granted to innovative medical devices2.


The role of QuiremScout® microspheres is to evaluate the expected safety and efficacy of the Selective Internal Radiation Therapy (SIRT). QuiremScout® microspheres are based on the same Holmium-166 microspheres as the therapeutic treatment (QuiremSpheres®). QuiremScout® microspheres are intended to evaluate lung-shunt3 and extrahepatic deposition3as part of the SIRT work-up. Moreover, they are intended for evaluation of the intrahepatic distribution3 during the work-up, which can be used to plan the SIRT treatment4.

Currently, 99mTc-MAA is most often used during the pre-treatment work-up of the SIRT treatment algorithm4.

However, QuiremScout® has recently proven to be more accurate in terms of intrahepatic targeting5 and lung shunt assessment6 compared to 99mTc-MAA during the work-up. The usage of QuiremScout® microspheres may allow physicians to improve their SIRT treatment planning4.


Recent clinical results continue to support the validation of QuiremScout® microspheres in patient selection and planning as part of the Holmium Platform, such as the latest publication in the Lancet Oncology Journal from UMC Utrecht for the non-randomized HEPAR PLuS study7, which included Neuroendocrine tumor (NET) patients with liver metastasis after systemic radiation therapy with 177Lu-Dotatate.


The Holmium platform consists of three integrated products (QuiremScout®, QuiremSpheres® & Q-suite™), which equips physicians with the necessary tools to optimize SIRT outcomes through more individualized treatment.


"QuiremScout is part of the Holmium platform that enables physicians to perform Selective intra-arterial radiation therapy. This technology uniquely allows a fine patient selection and individualized treatment for better outcomes. At Terumo, we are proud of this important recognition by the community.", said Laurent Domas, Vice President Global Interventional Oncology & Therapy Development, Terumo Interventional Systems.

Learn more about SIRT, the Holmium Platform and how patients with non-resectable liver disease may benefit from QuiremScout® microspheres.


About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for nearly 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide, to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been bolstering healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Terumo has completed the acquisition of Quirem Medical B.V., a Netherlands-based healthcare startup specializing in the development of next-generation microspheres for Selective Internal Radiation Therapy (SIRT), a treatment for liver tumors


About Terumo Europe

Terumo Europe, founded in 1971, is a core player in the EMEA healthcare market by providing best in class quality medical products and services. We are a strong actor of the Terumo Group by contributing to innovation and sustainable growth. Terumo Europe produces, distributes, markets and sells a vast range of medical devices in four main business units: Hospital and Laboratory Systems, Global Pharmaceutical Solutions, Interventional Systems and CardioVascular Products. Terumo Europe EMEA headquarters and production facilities are located in Haasrode (Belgium), production facility in Knowsley (UK) and sales units across EMEA.

Please visit for more information.



  3. Instructions for Use- QuiremScout® (rev 05)
  4. Chiesa & Maccauro, 2020 EJNMM
  5. Smits et al., 2019 EJNMM
  6. Elschot et al., 2014 EJNMM
  7. Braat et. Al. 2020, Lancet Oncology